DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Ewing sarcoma — screening already-approved drugs against its 37-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEwing sarcoma maps to a 37-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedPaclitaxelApproved drug
Structures already discussed alongside ewing sarcoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Refined structure of alpha-beta tubulin from zinc-induced sheets stabilized — Paclitaxel has a real, experimentally solved structure in complex with this target (PDB 1JFF, 3.5 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet ta1drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1JFF · 3.5 Å · ligand Paclitaxel (TA1). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Oncology Pharmacy Practice · 2020 · 7 citations
Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report
AbstractINTRODUCTION: Although, immune check-point inhibitors changed the course of many cancers, the outcomes in sarcomas were rather disappointing with less than 10% response rates. Ewing sarcoma is a poorly differentiated and aggressive tumor mostly seen in the children and adolescents. It's a distinct type of sarcoma with prominent chemosensitivity in the early stages. However, the relapsing disease has a poor prognosis with limited treatment options. CASE REPORT: The patient had a very good response to salvage treatment with a combination of paclitaxel and nivolumab which lasted for twelve months after the cessation of treatment. DISCUSSION: We think that chemotherapy plus immunotherapy can be an option for Ewing sarcoma patients treated with multiple lines of chemotherapy.
Iowa Research Online (The University of Iowa) · 2024 · 0 citations · open access
Targeting DNA replication stress in Ewing sarcoma
AbstractThe standard of care for Ewing sarcoma in North America has not changed in over two decades. It consists of chemotherapy prior to surgical and/or radiological intervention, followed by several additional cycles of chemotherapy. Unfortunately, it is only marginally effective for patients with recurrent and metastatic disease and is associated with significant off-target toxicity. Thus, the development of novel treatments is urgently needed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
